Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.
The Company continues to work with the U.S. Food and Drug Administration (FDA) during its review of its New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia, in advance of the February 26, 2024 PDUFA date.
“We remain committed to bringing roluperidone to patients and physicians as we believe it addresses a significant unmet clinical need and has the potential to improve patients’ quality of life and expand treatment options available to physicians. If approved, roluperidone would be the first medication for negative symptoms of schizophrenia to receive regulatory approval,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.
Third Quarter 2023 Financial Results
- Research and development (R&D) expense: For the three months ended September 30, 2023 and 2022, R&D expense was $3.4 million and $2.4 million, respectively. R&D expense was higher versus the prior year primarily due to costs associated with the FDA’s review of the Company’s NDA. For the nine months ended September 30, 2023 and 2022, R&D expense was $8.0 million and $11.5 million, respectively. The decrease in R&D expense versus the prior year was primarily due to higher costs in 2022 related to the preparation of the NDA for roluperidone, which was submitted in August 2022.
- General and administrative (G&A) expense: For the three months ended September 30, 2023 and 2022, G&A expense was $2.6 million and $2.8 million, respectively. For the nine months ended September 30, 2023 and 2022, G&A expense was $8.0 million and $8.7 million, respectively. The decrease in G&A expense for the three and nine-months ended September 30, 2023 versus the prior year was primarily due to lower non-cash stock compensation costs.
- Non-cash interest expense: For the three months ended September 30, 2023 and 2022, non-cash interest expense for the sale of future royalties was $2.1 million and $1.9 million, respectively. For the nine months ended September 30, 2023 and 2022, non-cash interest expense was $6.1 million and $5.5 million, respectively. The Company amortizes non-cash interest expense for the difference between the balance of the liability related to the sale of future royalties and the estimated amount future royalties to be received over the royalty period.
- Net loss: Net loss was $7.8 million for the three months ended September 30, 2023, or net loss per share of $1.03 basic and diluted, as compared to net loss of $6.9 million, or net loss per share of $1.29 basic and diluted, for the three months ended September 30, 2022. Net loss was $21.0 million for the nine months ended September 30, 2023, or net loss per share of $3.41 basic and diluted, as compared to net loss of $25.4 million, or net loss per share of $4.75 basic and diluted for the nine months ended September 30, 2022.
- Cash Position: Cash, cash equivalents and restricted cash at September 30, 2023, were approximately $47.0 million, as compared to $36.2 million at December 31, 2022.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (f/k/a MIN-101), for negative symptoms of schizophrenia, and MIN-301, for Parkinson’s disease. For more information, please visit our website.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to the regulatory progress and therapeutic potential of roluperidone for the treatment of negative symptoms in patients with schizophrenia. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether the FDA will require additional trials or data which may significantly delay and put at risk our efforts to obtain regulatory approval; whether the FDA may meet expected review timelines for our NDA; whether roluperidone will be successfully marketed if approved; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations and corporate objectives on terms acceptable to us; general economic conditions; and other factors that are described under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 8, 2023, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Copies of reports filed with the SEC are posted on our website athttp://ir.minervaneurosciences.com/. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
Chief Financial Officer
Minerva Neurosciences, Inc.
Shik Communications LLC
|CONDENSED CONSOLIDATED BALANCE SHEET DATA|
|September 30, 2023||December 31, 2022|
|Cash and cash equivalents||$||46,904||$||36,094|
|Refundable regulatory fee||-||3,117|
|Prepaid expenses and other current assets||1,221||848|
|Total current assets||48,225||40,159|
|Equipment & capitalized software, net||36||59|
|LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY|
|Accrued expenses and other current liabilities||1,955||408|
|Total current liabilities||3,350||1,377|
|Liability related to the sale of future royalties||79,826||73,734|
|Stockholders' (Deficit) Equity:|
|Additional paid-in capital||367,746||346,785|
|Total stockholders' (deficit) equity||(20,046||)||(20,024||)|
|Total Liabilities and Stockholders' (Deficit) Equity||$||63,130||$||55,087|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three Months Ended September 30,|
(in thousands, except per share amounts)
|Nine Months Ended September 30|
(in thousands, except per share amounts)
|Research and development||$||3,444||$||2,367||$||7,985||$||11,459|
|General and administrative||2,635||2,840||7,963||8,703|
|Total operating expenses||6,079||5,207||15,948||20,162|
|Loss from operations||(6,079||)||(5,207||)||(15,948||)||(20,162||)|
|Foreign exchange (losses) gains||(5||)||2||(21||)||-|
|Non-cash interest expense for the sale of future royalties||(2,085||)||(1,875||)||(6,093||)||(5,481||)|
|Net loss per share, basic and diluted||$||(1.03||)||$||(1.29||)||$||(3.41||)||$||(4.75||)|
|Weighted average shares outstanding, basic and diluted||7,569||5,340||6,148||5,340|
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu
Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding
September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202
Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release
September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th
Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse
Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er
Registration of share capital increase in IDEX Biometrics 1 Dec 20231.12.2023 17:30:00 CET | Press release
Reference is made to the notice on 21 November 2023 regarding employees having exercised 389,608 incentive subscription rights at NOK 0.15 per share. The capital increase has been registered and the shares will be delivered soonest. Following the issue, the company's share capital is NOK 209,551,597.20 divided into 1,397,010,648 shares, each with a nominal value of NOK 0.15. For further information contact: Marianne Bøe, Investor Relations E-mail: firstname.lastname@example.org Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As